Kivu Bioscience Names Brunilda Shtylla as Chief Business Officer to Lead Strategic Growth and Partnership Initiatives
Kivu Bioscience, a clinical-stage biotechnology company dedicated to advancing next-generation antibody-drug conjugates (ADCs) for the treatment of difficult-to-treat cancers, has announced the appointment of Brunilda Shtylla as its new Chief Business Officer. The strategic leadership addition comes at a pivotal time for the company as it continues to progress its pipeline of differentiated ADC candidates through clinical development and deepens its focus on building high-value partnerships to expand its technological and commercial footprint.
In her new role, Shtylla will oversee corporate strategy, business development, and partnership initiatives. She will be responsible for shaping the company’s long-term growth trajectory, identifying and structuring strategic collaborations, and supporting capital formation initiatives as Kivu advances its clinical programs and broadens its innovation ecosystem. Her appointment reflects the company’s commitment to strengthening its executive leadership team as it moves toward key clinical milestones and seeks to maximize the value of its proprietary ADC platform.
Kivu Bioscience has emerged as an innovative player in the rapidly evolving ADC landscape, a therapeutic modality that combines the specificity of monoclonal antibodies with the potent cell-killing ability of cytotoxic agents. ADCs are designed to selectively deliver powerful payloads directly to cancer cells while sparing healthy tissue, thereby improving efficacy and reducing systemic toxicity. Over the past decade, the field has witnessed significant scientific and commercial breakthroughs, validating ADCs as a transformative class of oncology therapeutics. Against this backdrop, Kivu has positioned itself to develop next-generation ADCs aimed at addressing cancers that remain resistant to currently available treatments.
The company’s platform emphasizes rational design, optimized linker chemistry, and carefully selected payloads to enhance therapeutic index and overcome common resistance mechanisms. With one clinical-stage asset already advancing and a second candidate expected to enter clinical development, Kivu is entering a period marked by increasing operational complexity, expanded clinical execution, and growing partnership opportunities. Shtylla’s arrival is intended to help guide the company through this critical growth phase.
Brunilda Shtylla brings more than 25 years of experience spanning biotechnology, medical devices, financial strategy, and complex strategic transactions. Her career has been defined by a consistent ability to bridge scientific innovation with financial and commercial execution, enabling emerging and established companies alike to unlock substantial value through partnerships, licensing agreements, and strategic alliances.
Most recently, Shtylla served as Chief Business Officer at Sutro Biopharma, where she led business strategy and corporate development efforts. During her tenure, she played a central role in advancing Sutro’s cell-free protein synthesis platform through a series of collaborations, licensing deals, and strategic partnerships. Her leadership contributed to securing more than $5.5 billion in total deal value, underscoring her expertise in negotiating complex agreements that align scientific potential with commercial opportunity. At Sutro, she demonstrated a keen understanding of how to position differentiated technologies in a competitive marketplace while ensuring long-term value creation for shareholders and partners.
Prior to her work at Sutro, Shtylla advised several prominent organizations across the life sciences ecosystem. Among them were Genentech, GRAIL, and Edwards Lifesciences. In these advisory capacities, she provided strategic insight into corporate transactions, growth planning, and market positioning. Her experience working alongside both innovative biotech firms and established industry leaders has given her a nuanced perspective on how to scale emerging technologies, structure win-win collaborations, and navigate evolving regulatory and reimbursement landscapes.
Earlier in her career, Shtylla held leadership roles at LifeScan, a company within the Johnson & Johnson family. There, she gained firsthand experience in global healthcare operations, commercialization strategy, and cross-functional leadership. Exposure to large-scale healthcare infrastructure complemented her background in finance and mathematics, equipping her with analytical rigor and operational discipline that have become hallmarks of her professional approach.
Commenting on the appointment, Mohit Trikha, Ph.D., President and Chief Operating Officer of Kivu Bioscience, emphasized the strategic importance of Shtylla’s experience. He described her as a highly accomplished executive with a demonstrated ability to structure innovative partnerships and create enduring strategic value. According to Trikha, as Kivu prepares to move its second ADC candidate into clinical development and expand internal capabilities, her expertise will be instrumental in accelerating the company’s growth and advancing novel therapies for patients facing limited treatment options.
The oncology landscape remains characterized by high unmet medical need, particularly in aggressive and refractory tumor types. Despite advances in immuno-oncology, targeted therapies, and precision medicine, many cancers continue to evade durable responses. ADCs represent one of the most promising modalities to address these gaps, offering the potential for enhanced tumor targeting and improved therapeutic outcomes. However, successful development requires not only scientific excellence but also robust strategic planning, capital access, and collaborative networks that extend across research institutions, pharmaceutical partners, and global markets.
Shtylla’s appointment signals Kivu’s recognition that business development and corporate strategy are integral to translating scientific innovation into patient impact. As Chief Business Officer, she will work closely with the executive team to evaluate co-development opportunities, explore regional licensing arrangements, and potentially establish broader strategic alliances that can accelerate clinical timelines and expand geographic reach. She will also help refine the company’s long-term vision as it navigates regulatory pathways, competitive dynamics, and evolving investor expectations.
In her own remarks, Shtylla expressed enthusiasm about joining Kivu at this inflection point. She highlighted the company’s differentiated ADC platform and advancing pipeline as key factors that attracted her to the role. She noted that Kivu’s thoughtful, disciplined approach to development, combined with its ability to execute rapidly, positions the company to deliver meaningful innovation in targeted cancer therapies.
Shtylla also emphasized the importance of teamwork and alignment in achieving ambitious scientific goals. She described being impressed by the caliber and commitment of Kivu’s team and expressed eagerness to collaborate across functions to build strategic partnerships, accelerate pipeline advancement, and ultimately bring new treatment options to patients. Her comments underscored a shared belief within the organization that scientific differentiation must be matched by operational excellence and strategic foresight.
The broader ADC market has seen increased interest from large pharmaceutical companies seeking to expand their oncology portfolios. High-profile acquisitions and licensing deals in recent years have demonstrated strong appetite for next-generation ADC technologies, particularly those that can overcome resistance, enhance payload potency, or broaden applicability across tumor types. For emerging biotech companies like Kivu, this environment creates both opportunity and competition. Strategic leadership capable of navigating partnership negotiations while preserving long-term value becomes critical.
With Shtylla’s track record of generating multi-billion-dollar deal value and fostering durable collaborations, Kivu is positioning itself to engage proactively with potential partners while maintaining focus on its core mission. Her expertise in structuring agreements that balance upfront capital, milestone payments, and long-term royalties could play a significant role in shaping how Kivu funds its clinical programs and expands its global reach.
Beyond transactions, her responsibilities will likely encompass investor relations support, portfolio prioritization, and evaluation of potential in-licensing or platform expansion opportunities. As clinical data emerge from Kivu’s pipeline, the ability to contextualize results within the broader oncology landscape and communicate value propositions clearly to stakeholders will be increasingly important. Shtylla’s multidisciplinary background—combining finance, mathematics, and business leadership—positions her well to guide these efforts.
Academically, Shtylla holds an MBA from the Stanford Graduate School of Business, an MS in Mathematics from Youngstown State University, and a BS in Business from Wayne State University. Her educational background reflects a blend of quantitative expertise and strategic management training, reinforcing the analytical and operational strengths she brings to executive leadership.
As Kivu Bioscience continues to evolve from a clinical-stage innovator into a more broadly positioned oncology company, leadership depth will be central to sustaining momentum. The addition of Brunilda Shtylla as Chief Business Officer marks a deliberate step toward reinforcing the company’s commercial and strategic capabilities at a time when the ADC field is gaining unprecedented validation and investor attention.
Ultimately, the success of next-generation oncology therapies depends on seamless integration of scientific discovery, clinical execution, regulatory navigation, and strategic collaboration. By strengthening its executive team with seasoned leadership in business development and corporate strategy, Kivu aims to accelerate its path toward delivering differentiated ADC therapies to patients with limited treatment options. Shtylla’s appointment not only reflects confidence in the company’s scientific platform but also signals an ambition to build enduring partnerships that can amplify its impact in the fight against cancer.
Source Link: https://www.businesswire.com/
